NCT03676231 - Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG

SGM-1019

Active

DRUG

Placebo

Inactive

Trial Locations (10)

Second Genome Clinical Site 408, Fayetteville

Second Genome Clinical Site 409, Lakewood Rch

Second Genome Clinical Site 407, Clarksville

Second Genome Clinical Site 410, Flowood

Second Genome Clinical Site 404, Kansas City

Second Genome Clinical Site 401, San Antonio

Second Genome Clinical Site 402, Austin

Second Genome Clinical Site 405, Chandler

Second Genome Clinical Site 406, Tucson

Second Genome Clinical Site 403, Panorama City